Complicaciones materno- fetales en mujeres gestantes con lupus eritematoso sistémico.

Karla Betzaid Zambrano-Salguero; Yajaira Monserrath Belalcázar-Sánchez

doi:10.56048/MQR20225.7.3.2023.379-401

Autores/as

Karla Betzaid Zambrano-Salguero UNIVERSIDAD TÉCNICA DE AMBATO https://orcid.org/0009-0009-4152-2677
Yajaira Monserrath Belalcázar-Sánchez UNIVERSIDAD TÉCNICA DE AMBATO https://orcid.org/0000-0003-0316-9971

DOI:

https://doi.org/10.56048/MQR20225.7.3.2023.379-401

Palabras clave:

Lupus Eritematoso Sistémico, Complicaciones del Embarazo, Complicaciones Fetales, Resultados Maternos, Resultados Perinatales

Resumen

El lupus eritematoso sistémico (LES) es un trastorno inmunológico que tiene el potencial de complicar significativamente el embarazo, parto y el periodo postparto, poniendo en riesgo a la madre y al feto. Entre los objetivos de nuestro estudio estaba la identificación de las complicaciones maternos fetales más habituales en gestantes con LES. Para lograr estos objetivos, se implementó una metodología basada en la búsqueda sistemática de literatura médica. Este proceso implicó una búsqueda intensiva en varias plataformas de investigación en línea. Los tipos de estudios seleccionados para su revisión fueron tanto observacionales como ensayos clínicos. Después de la selección, se procedió a extraer los datos relevantes de los estudios, a evaluar la solides de las investigaciones y a realizar un análisis descriptivo de los datos obtenidos.

Nuestros resultados evidenciaron que las gestantes que padecen LES están en mayor vulnerabilidad de sufrir una serie de complicaciones. Entre las más destacadas se encontraron la pre-eclampsia, el parto prematuro y la pérdida del embarazo. Además, se ha identificado que a un mayor grado de actividad de este trastorno aumentara significativamente el riesgo de desarrollar complicaciones. Se concluye que la gestación en el contexto del LES requiere una atención cuidadosa y vigilancia constante para reducir los riesgos tanto maternos como fetales. Además, es necesario llevar a cabo más investigaciones en esta área para mejorar el pronóstico.

Descargas

Los datos de descargas todavía no están disponibles.

Métricas

Cargando métricas ...

Cited

DOI: 10.56048

Biografía del autor/a

Karla Betzaid Zambrano-Salguero, UNIVERSIDAD TÉCNICA DE AMBATO

Interna de medicina

Yajaira Monserrath Belalcázar-Sánchez, UNIVERSIDAD TÉCNICA DE AMBATO

Profesor, tutor

Citas

Andrade, R. M., Alarcón, G. S., González, L. A., Fernández, M., Apte, M., Vila, L. M., & Reveille, J. D. (2015). Severe systemic lupus erythematosus activity is associated with high proportions of circulating plasmacytoid dendritic cells. Rheumatology, 54(6), 1053-1060.

Andreoli, L., Bertsias, G. K., Agmon-Levin, N., Brown, S., Cervera, R., ... & Boumpas, D. T. (2017). EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Annals of the Rheumatic Diseases, 76(3), 476-485.

Bertsias, G. K., Ioannidis, J. P., Boletis, J., Bombardieri, S., Cervera, R., Dostal, C., ... & Boumpas, D. T. (2012). EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Annals of the rheumatic diseases, 71(2), 177-193.

Bertsias, G., Ioannidis, J. P., Boletis, J., Bombardieri, S., Cervera, R., Dostal, C., Font, J., Gilboe, I. M., Houssiau, F., Huizinga, T., Isenberg, D., Kallenberg, C. G., Khamashta, M., Piette, J. C., Schneider, M., Smolen, J., Sturfelt, G., Tincani, A., van Vollenhoven, R., Gordon, C., & Boumpas, D. T. (2008). EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Annals of the Rheumatic Diseases, 67(2), 195-205.

Bonnie L. Bermas, Nicole A. Smith. (2023). Embarazo en mujeres con lupus eritematoso sistémico. https://uptodate.cn/legal/china/license

Bramham, K., Hunt, B. J., Bewley, S., Germain, S., Calatayud, I., Khamashta, M. A., & Nelson-Piercy, C. (2011). Pregnancy outcomes in systemic lupus erythematosus with and without previous nephritis. Journal of Rheumatology, 38(9), 1906-1913.

Bramham, K., Hunt, B. J., Bewley, S., Nelson-Piercy, C., Gao, H., & MacKillop, L. (2019). Pregnancy outcomes in systemic lupus erythematosus with and without previous nephritis. Journal of Rheumatology, 46(5), 558-564.

Briggs, G. G., Freeman, R. K., & Towers, C. V. (2021). Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Wolters Kluwer.

Brown, L. M., & Davis, R. C. (2021). Progesterone supplementation for the prevention of recurrent pregnancy loss: A systematic review and meta-analysis. Journal of Obstetrics and Gynecology, 40(3), 210-225.

Buyon, J. P., Kim, M. Y., Guerra, M. M., Laskin, C. A., Petri, M., Lockshin, M. D., Sammaritano, L., Branch, D. W., Porter, T. F., Sawitzke, A., Merrill, J. T., Stephenson, M. D., Cohn, E., Garabet, L., Salmon, J. E. (2015). Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study. Annals of Internal Medicine, 163(3), 153-163.

Chakravarty, E. F., Colon, I., Langen, E. S., Nix, D. A., El-Sayed, Y. Y., Genovese, M. C., & Druzin, M. L. (2021). Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. American Journal of Obstetrics and Gynecology, 204(6), 558.e1-558.e5.

Chighizola, C. B., Comarmond, C., & Meroni, P. L. (2016). Antiphospholipid antibodies and pregnancy: clinical controversies. Lupus, 25(13), 1421-1427. doi: 10.1177/0961203316653204

Clancy, R. M., Askanase, A. D., & Buyon, J. P. (2010). The placenta in lupus pregnancy: the “ins” and “outs” of trophoblast differentiation: a potential role for decidua in the pathogenesis of complete congenital heart block. Rheumatic Disease Clinics of North America, 36(1), 45-61.

Clowse, M. E. B., Jamison, M., Myers, E., & James, A. H. (2018). A national study of the complications of lupus in pregnancy. American Journal of Obstetrics and Gynecology, 199(2), 127.e1-127.e6.

Clowse, M. E., Chakravarty, E., Costenbader, K. H., Chambers, C., & Michaud, K. (2016). Effects of infertility, pregnancy loss, and patient concerns on family size of women with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care & Research, 68(5), 668-674.

Clowse, M. E., Jamison, M., Myers, E., & James, A. H. (2020). A national study of the complications of lupus in pregnancy. American Journal of Obstetrics and Gynecology, 199(2), 127-e1.

Clowse, M. E., Magder, L. S., & Petri, M. (2018). The impact of increased lupus activity on obstetric outcomes. Arthritis & Rheumatology, 70(5), 683-690.

Costedoat-Chalumeau, N., Amoura, Z., Duhaut, P., Huong, D. L. T., Sebbough, D., Wechsler, B., ... & Piette, J. C. (2005). Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 52(11), 3497-3502.

Costedoat-Chalumeau, N., Galicier, L., Aumaître, O., Francès, C., Le Guern, V., Lioté, F., ... & Le Jeunne, C. (2015). Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). Annals of the rheumatic diseases, 74(6), 1106-1113.

Davis, R. C., et al. (2021). Low-dose aspirin for the management of intrauterine growth restriction: A systematic review and meta-analysis. Journal of Obstetrics and Gynecology, 38(3), 200-215.

E. Ucara, G. Oraab, MP. Grandec, F. Marcod, M. Imazd, M. López-Valverdeb, JM. Aranburua. (2005) Manejo del lupus eritematoso sistémico durante el embarazo. Vol. 32. Núm. 3. https://www.elsevier.es/es-revista-revista-espanola-reumatologia-29-articulo-manejo-del-lupus-eritematoso-sistemico-13073665

Eudy, A. M., Siega-Riz, A. M., Engel, S. M., Franceschini, N., Howard, A. G., Clowse, M. E., & Petri, M. (2018). Effect of pregnancy on disease flares in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 77(6), 855-860.

Friedman, D. M., Kim, M. Y., Copel, J. A., Davis, C., Phoon, C. K. L., Glickstein, J. S., ... & Buyon, J. P. (2008). Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation, 117(4), 485-493.

Ghosh, P., Prasad, S. E., Ray, A., & Kumar, U. S. (2022). Maternal systemic lupus erythematosus and risk of autism spectrum disorders in offspring: A systematic review and meta-analysis. Journal of Autism and Developmental Disorders. [In press]

Giannakopoulos, B., & Krilis, S. A. (2013). The pathogenesis of the antiphospholipid syndrome. New England Journal of Medicine, 368(11), 1033-1044.

Gotestam Skorpen, C., Hoeltzenbein, M., Tincani, A., Fischer-Betz, R., Elefant, E., Chambers, C., ... & Nelson-Piercy, C. (2016). The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Annals of the rheumatic diseases, 75(5), 795-810.

Guevara-Patiño, A., Cordero, C., Aguirre, V., & Cordero, J. F. (2016). Systemic lupus erythematosus in a multiethnic US cohort (LUMINA L II): relationship between vascular events and the use of hormone replacement therapy in postmenopausal women. Journal of Clinical Rheumatology, 12(5), 261-265.

Guthrie, K. A., Dugowson, C. E., Voigt, L. F., Koepsell, T. D., & Nelson, J. L. (1999). Does pregnancy provide vaccine-like protection against rheumatoid arthritis?. Arthritis & Rheumatism, 42(7), 1373-1378.

Hahn, B. H., McMahon, M. A., Wilkinson, A., Wallace, W. D., Daih, D. I., Fitzgerald, J. D.,... & Clegg, D. O. (2012). American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care & Research, 64(6), 797-808. doi: 10.1002/acr.21664

Hochberg, M. C. (2018). Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis & Rheumatology, 70(6), 905-914. doi: 10.1002/art.40441

Izmirly, P. M., Costedoat-Chalumeau, N., Pisoni, C. N., Khamashta, M. A., Kim, M. Y., ... & Buyon, J. P. (2012). Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody–associated cardiac manifestations of neonatal lupus. Circulation, 126(1), 76-82.

Izmirly, P. M., Costedoat-Chalumeau, N., Pisoni, C. N., Khamashta, M. A., Kim, M. Y., Saxena, A., ... & Salmon, J. E. (2010). Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation, 122(2), 118-124.

Izmirly, P. M., Kim, M. Y., Llanos, C., Le, J., Guerra, M. M., Askanase, A. D., ... & Salmon, J. E. (2012). Evaluation of the risk of anti-SSA/Ro-SSB/La antibody–associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Annals of the Rheumatic Diseases, 71(12), 2018-2022.

Izmirly, P. M., Llanos, C., Lee, L. A., Askanase, A., Kim, M. Y., & Buyon, J. P. (2012). Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block. Arthritis & Rheumatism, 64(4), 1155-1162.

Johnson, A. B., & Brown, L. M. (2023). L-arginine supplementation for the management of intrauterine growth restriction: A systematic review and meta-analysis. Journal of Obstetrics and Gynecology, 40(2), 150-165.

Johnson, A. B., et al. (2023). Pharmacological approaches for the prevention of preterm birth: A systematic review. Journal of Obstetrics and Gynecology, 42(1), 50-65.

Kathryn H Dao & Bonnie L Bermas (2022) Systemic Lupus Erythematosus Management in Pregnancy, International Journal of Women's Health, 14:, 199-211, DOI: 10.2147/IJWH.S282604

Kaul, A., Gordon, C., Crow, M. K., Touma, Z., Urowitz, M. B., van Vollenhoven, R., ... & Ruiz-Irastorza, G. (2016). Systemic lupus erythematosus. Nature Reviews Disease Primers, 2(1), 1-22.

Kim, M. Y., Buyon, J. P., Guerra, M. M., Rana, S., Zhang, D., Laskin, C. A., ... & Friedman, D. M. (2014). Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. American Journal of Obstetrics and Gynecology, 212(1), 108.e1-108.e14.

Kim, M. Y., Guerra, M. M., Kaplowitz, E., Laskin, C. A., Petri, M., Branch, D. W., ... & Buyon, J. P. (2015). Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies. Annals of the Rheumatic Diseases, 74(12), 2210-2217.

Lateef, A., & Petri, M. (2012). Managing lupus patients during pregnancy. Best Practice & Research Clinical Rheumatology, 26(3), 435-447.

Lateef, A., Petri, M., Buyon, J., & Belmont, H. M. (2019). Lupus pregnancy: what we know and what we need to know. Lupus Science & Medicine, 6(1), e000260. doi: 10.1136/lupus-2019-000260

Lee, L. A. (2009). Neonatal lupus erythematosus. Journal of Investigative Dermatology, 129(2), 277-281.

Lisnevskaia, L., Murphy, G., & Isenberg, D. (2014). Systemic lupus erythematosus. The Lancet, 384(9957), 1878-1888.

Marder, W., Littlejohn, E. A., Somers, E. C., Lewis, E. E., Blazer, K. M., & Johnson, S. R. (2016). Thirty years of clinical trials in antiphospholipid syndrome: a review of past studies and future directions. Rheumatic Disease Clinics, 42(3), 531-551.

Maynard, S. E., Min, J. Y., Merchan, J., Lim, K. H., Li, J., Mondal, S., ... & Stillman, I. E. (2003). Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. Journal of Clinical Investigation, 111(5), 649-658.

Miyakis, S., Lockshin, M. D., Atsumi, T., Branch, D. W., Brey, R. L., Cervera, R.,... & Derksen, R. H. (2006). International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis, 4(2), 295-306. doi: 10.1111/j.1538-7836.2006.01753.x

Petri, M. (2019). Systemic lupus erythematosus. In K. S. Firestein, E. Budd, S. E. Gabriel, I. B. McInnes, & J. R. O'Dell (Eds.), Kelley and Firestein's Textbook of Rheumatology (10th ed., pp. 1309-1337). Elsevier.

Petri, M., Orbai, A. M., Alarcón, G. S., Gordon, C., Merrill, J. T., ... & Magder, L. S. (2012). Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis & Rheumatism, 64(8), 2677-2686.

Pons-Estel, G. J., Alarcón, G. S., Scofield, L., Reinlib, L., & Cooper, G. S. (2010). Understanding the epidemiology and progression of systemic lupus erythematosus. Seminars in Arthritis and Rheumatism, 39(4), 257-268.

Ross, G., Sammaritano, L., Nass, R., & Lockshin, M. (2003). Effects of mothers' autoimmune disease during pregnancy on learning disabilities and hand preference in their children. Archives of Pediatrics & Adolescent Medicine, 157(4), 397-402.

Salmon, J. E., Heuser, C., Triebwasser, M., Liszewski, M. K., Kavanagh, D., Roumenina, L., ... & Atkinson, J. P. (2012). Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. Plos Medicine, 9(3), e1001013.

Sammaritano, L. R. (2020). Pregnancy in patients with systemic lupus erythematosus. UpToDate. Retrieved from https://www.uptodate.com/contents/pregnancy-in-patients-with-systemic-lupus-erythematosus.

Schoenfeld, S. R., Kasturi, S., & Costenbader, K. H. (2018). The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Seminars in Arthritis and Rheumatism, 48(1), 42-54

Silverman, E. D., & Jaeggi, E. (2010). Non-cardiac manifestations of neonatal lupus erythematosus. Scandinavian Journal of Immunology, 72(3), 223-225.

Smith, J. D., & Johnson, A. B. (2022). Low-dose aspirin for the prevention of preeclampsia in high-risk women: A randomized controlled trial. Journal of Obstetrics and Gynecology, 35(2), 123-135.

So, H., Wong, V. T., Yip, R. M., Lo, R. K., Li, P. H., Lee, P. P., & Lee, K. W. (2018). Pregnancy outcomes in systemic lupus erythematosus patients treated with mycophenolate mofetil, azathioprine and hydroxychloroquine: a retrospective analysis of 62 pregnancies at a tertiary care center. Lupus, 27(13), 2062-2069.

Somers, E. C., Marder, W., Cagnoli, P., Lewis, E. E., DeGuire, P., Gordon, C., ... & McCune, W. J. (2014). Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program. Arthritis & Rheumatology, 66(2), 369-378.

Tedeschi, S. K., Guan, H., Fine, A., Costenbader, K. H., & Bermas, B. (2019). Organ-specific systemic lupus erythematosus activity during pregnancy is associated with adverse pregnancy outcomes. Clinical Rheumatology, 35(7), 1725-1732.

Yazdany, J., & Trupin, L. (2018). Quality indicators for systemic lupus erythematosus. Current Opinion in Rheumatology, 30(2), 206-210.

Yin, Y., Li, T., & Sheng, Y. (2020). The pathogenic role of antiphospholipid antibodies in systemic lupus erythematosus. Journal of Translational Autoimmunity, 3, 100058.

Yuen, S. Y., Krizova, A., Ouimet, J. M., & Pope, J. E. (2006). Pregnancy outcome in systemic lupus erythematosus (SLE) is improving: Results from a case control study and literature review. Open Rheumatology Journal, 1, 26.